Literature DB >> 7861542

Immunohistochemical localization of glucose transporters in human renal cell carcinoma.

Y Nagase1, K Takata, N Moriyama, Y Aso, T Murakami, H Hirano.   

Abstract

The localization of 2 isoforms of glucose transporters (GLUT1 and GLUT4) in 75 patients with renal cell carcinoma was examined immunohistochemically. Paraffin sections were immunostained with either anti-GLUT1 or GLUT4 antibody by the avidin-biotin-peroxidase complex method. In 55 of 75 patients, GLUT1 staining was demonstrated at the plasma membrane of the cancer cells. In the clear cell subtype, 44 of 52 (84.6%) patients were positive for GLUT1. We did not detect positive staining for GLUT1 in the spindle cell type. In the mixed cell subtype, positive staining was recognized in only the areas of clear cell carcinomas (10 of 13; 76.9%). Positive staining for GLUT1 did not show any significant correlation with tumor grade or extent. Heterogeneous expression of GLUT1 was observed in tumor cell mass: some tumor cells were positive for GLUT1, while other cells were not. In adjacent normal tissue, GLUT1 staining was only recognized at the plasma membrane of some renal tubules. GLUT4 staining was not recognized in either tumor or normal tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7861542

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 2.  Targeting glycogen metabolism in bladder cancer.

Authors:  Carolyn Ritterson Lew; Sunny Guin; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

Review 3.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

4.  Immunohistochemical expression of glucose transporter-1 in human penile proliferative lesions.

Authors:  N Moriyama; S Kurimoto; K Kawabe; K Takata; H Hirano
Journal:  Histochem J       Date:  1997-04

Review 5.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

6.  Development of a novel class of glucose transporter inhibitors.

Authors:  Dasheng Wang; Po-Chen Chu; Chia-Ning Yang; Ribai Yan; Yu-Chung Chuang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2012-04-10       Impact factor: 7.446

7.  Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas.

Authors:  Young Jin Jun; Se Min Jang; Hu Lin Han; Kang Hong Lee; Ki-Seok Jang; Seung Sam Paik
Journal:  World J Gastroenterol       Date:  2011-04-14       Impact factor: 5.742

8.  Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis?

Authors:  Duangpen Thirabanjasak; Olca Basturk; Deniz Altinel; Jeanette D Cheng; N Volkan Adsay
Journal:  Pancreatology       Date:  2008-12-13       Impact factor: 3.996

9.  Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder.

Authors:  Henning Reis; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Kurt Werner Schmid; Florian Grabellus
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

10.  Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

Authors:  Jessica D Sun; Dharmendra Ahluwalia; Qian Liu; Wenwu Li; Yan Wang; Fanying Meng; Deepthi Bhupathi; Mark D Matteucci; Charles P Hart
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.